Кaiotkina Е.V., Chistyakova S.V., Кuvyrkova O.I.
THE RESULTS OF COMPLEX TREATMENT OF OCULAR ISCHEMIC SYNDROME ^{[№ 12 ' 2015]}
Ocular ischemic syndrome is one of the most difficult to treat pathological conditions of the eye with steadily progressive vision loss and a significant decline in the life quality of patients, especially in the elderly, leading to permanent disability. Often the main background of the disease with ocular ischemic syndrome is a chronic cerebrovascular pathology. In recent years there has been growth in ischemic diseases of the eye, which is associated with the spread of atherosclerosis, hypertension, coronary heart disease, diabetes, and cervical osteochondrosis. The article analyzes the results of complex treatment of patients with ocular ischemic syndrome. Among them were patients with open-angle compensated glaucoma, retinal degeneration, subatrophy of the optic nerve, age-related macular degeneration, nonproliferative diabetic retinopathy. Most patients were chronic cerebrovascular, cardiovascular, bronchopulmonary pathology. The control group received the standard neuroprotectors and angioprotectors, antioxidants and trophic preparations. In the main group in addition to standard treatment was prescribed nasal drops Semax 0,1 % (3 times a day for 20 days). The duration of treatment was 20 days. Treatment courses were repeated every 3–6 months. Comparative evaluation of treatment efficiency was carried out according to visometry and perimetry. In the intranasal use of drops Semax uncorrected visual acuity increased 1.7 times (from 0.18 to 0.32), corrected visual acuity increased 3.1 times (from 0.19 to 0.59). Field of vision increased by 10–15 degrees. Almost all patients of the main group (96 %) reported subjective improvement of vision, improving overall health, mood, increase concentration, improve memory, reduce irritability.